What Defines an Expert Polymorph Screening Service? A Look Inside XtalPi's Scientific Ecosystem

Summary:
The pharmaceutical industry's traditional approach to polymorph screening is increasingly challenged by late-appearing polymorph risks, escalating molecular complexity, and stringent regulatory demands. XtalPi's AI-driven polymorph screening service, powered by the XtalGazerTM platform (Website: https://www.xtalgazer.com), offers a paradigm shift. By integrating AI models with an automation-enhanced wet lab, the platform replaces empirical trial-and-error with rational experimental design. This creates a dry-wet lab closed-loop where AI predictions guide robotic experiments, and real-time data continuously refines the models. The result is a dramatic acceleration of the solid-state development timeline. This scientific ecosystem delivers not just speed, but the data integrity and predictive certainty required for modern drug development.

Introduction: The Imperative for a New Paradigm in Solid-State Development
For decades, the identification and selection of the optimal crystalline form of an Active Pharmaceutical Ingredient (API) has been a cornerstone of drug development. This process, known as polymorph screening, is critical as it directly impacts a drug's solubility, stability, bioavailability, manufacturability, and ultimately, its efficacy and safety profile. Traditionally, this has been a domain governed by manual experimentation, relying heavily on the experience of skilled scientists navigating a vast experimental space of solvents, temperatures, and crystallization techniques through a process of trial and error.
However, the landscape of pharmaceutical R&D is undergoing a seismic shift. The molecules entering pipelines today-such as molecular glues, PROTACs, and other complex new modalities-present unprecedented solid-state challenges. Concurrently, regulatory scrutiny on data completeness and the infamous specter of late-appearing polymorphs continue to loom large, threatening timelines and market viability. The traditional empirical approach is no longer sufficient; it is too slow, too resource-intensive, and inherently prone to oversight. The industry now demands a rational, predictive, and comprehensive methodology. This is where artificial intelligence, coupled with robotic automation, is fundamentally reshaping the paradigm, moving solid-state development from art to a predictable science.

The Core Pain Points: Why Traditional Polymorph Screening Falls Short
The limitations of conventional polymorph screening are not mere inefficiencies; they represent significant strategic and financial risks for drug developers.
•The Unacceptable Risk of Late-Appearing Polymorphs: Perhaps the most daunting challenge is the possibility that a more stable, previously undetected crystal form emerges after a drug is on the market or in late-stage development. Industry analyses suggest that for 15% to 45% of marketed drugs, the thermodynamically most stable form may not have been identified during initial screening. The case of Ritonavir remains a canonical warning: the appearance of a new, less soluble polymorph years post-approval necessitated a costly reformulation and nearly derailed the product. This risk is a multi-billion-dollar gamble on patient safety and product lifecycle.
•The Resource Drain of Experimental Screening: A comprehensive traditional screen is a monumental undertaking. It can span several months, consume hundreds of milligrams to grams of precious API-often when material is severely limited in early development-and require constant manual intervention from highly trained chemists. This creates a critical bottleneck, delaying formulation development and IND filings.
•The Inherent Limits of Empirical Design: Traditional screening is fundamentally reactive. Scientists design experiments based on precedent and chemical intuition, but the outcome of any given crystallization attempt is notoriously difficult to predict. This leads to an unavoidable "search in the dark" problem, where the experimental coverage of the vast chemical and process parameter space is inevitably incomplete, risking the omission of critical forms.
•The Challenge of Modern Molecular Complexity: New therapeutic modalities defy the rules of thumb developed for small molecules. Large, flexible molecules like PROTACs may have fewer preferred conformational states for stable packing, making crystal prediction and formation exponentially more difficult. Traditional solvent-based screens often fail to yield any crystalline material at all for these challenging compounds.
•Mounting Regulatory and Data Integrity Pressures: Global health authorities increasingly expect a scientifically justified polymorph screening strategy and a complete, auditable data trail. Manually recorded, paper-based processes are prone to error and gaps, making it difficult to demonstrate to regulators that the polymorph landscape has been thoroughly and defensibly explored.

The Transformative Value of AI-Driven Polymorph Screening
AI-driven polymorph screening addresses these pain points not by incrementally improving the old methods, but by re-engineering the entire process from first principles. The core value proposition is the shift from experimental observation to predictive design.
XtalPi's XtalGazerTM platform embodies this integrated, next-generation approach. It is not a single tool, but a cohesive scientific ecosystem built on two synergistic pillars: a powerful AI prediction engine and an automation-enhanced wet lab.

XtalGazerTM prioritizes transitioning from a high-material-requirement and high throughput screening approach to a model-first predictive approach. We have developed a number of computational tools that are made to design the experimental strategy for each API based on its unique structure. XtalGazerTM delivers higher hit rates and improved material and time efficiency compared to traditional methods through these predictive tools.
On the physical execution side, the platform features an automation-enhanced wet lab. This platform is designed to 100% cover conventional solution-based solid-state screening methods-including cooling crystallization, evaporation, slurry conversion, and anti-solvent addition-across thousands of unique experimental conditions. It operates with precision and consistency unattainable by human hands, all while meticulously logging every action and result as structured digital data.
The true genius of the XtalGazerTM platform lies in the seamless integration of its dry and wet components, creating a self-improving closed-loop iteration cycle.
1.AI-Guided Rational Design: Initially, the AI models analyze the target API's structure and predict its probable polymorph landscape. They then design a prioritized, minimal set of experiments aimed at either confirming the most promising predicted forms or deliberately challenging the prediction by targeting conditions where unexpected forms might appear.
2.Robotic Execution & Data Generation: The automated platform executes this designed campaign precisely, synthesizing and analyzing samples around the clock.
3.Continuous Learning & Model Refinement: The results-both positive (crystals identified) and negative (no crystal formed)-are fed back into the AI training pipelines in real time. This feedback continuously refines and improves the predictive models, making them smarter and more accurate for the next molecule. The loop between prediction and validation gets tighter with every cycle.
This flywheel effect transforms the process. It replaces the open-ended, empirical "let's try this" approach with a targeted, hypothesis-driven "we predict this, let's validate it" methodology. It ensures that every experiment yields maximum information value, progressively reducing uncertainty.

Practical Impact and Proven Outcomes
The operational benefits of this AI-driven ecosystem translate directly into tangible business and scientific value for pharmaceutical partners.
•Accelerated Timelines and Enhanced Efficiency: By front-loading the process with intelligent prediction and automating execution, the platform dramatically compresses the polymorph screening timeline, accelerating critical go/no-go decisions and getting molecules to patients faster.
•Comprehensive Landscape Mapping with Less API: The rational design of experiments means more knowledge is gained from less material. Campaigns are more efficient, requiring significantly lower quantities of precious API to achieve a defensibly comprehensive screen, a crucial advantage in early development.
•Validated Expertise and Collaboration: The platform's robustness is proven and is trusted in active collaborations with 17 of the global Top 20 pharmaceutical companies. A standout example is the work on nirmatrelvir, the antiviral component of PAXLOVID. During the urgent development of Pfizer's COVID-19 oral antiviral PAXLOVID, XtalPi collaborated closely with Pfizer's scientists. Utilizing XtalGazerTM platform, XtalPi helped confirm the advantageous pharmaceutical crystal form of nirmatrelvir. This computational-experimental synergy contributed to significantly accelerating the development timeline, enabling faster regulatory approval and deployment of this critical therapy. (Link: https://www.xtalgazer.com/tale-of-two-polymorphs-investigating-the-structural-differences-and-dynamic-relationship-between-nirmatrelvir-solid-forms-paxlovid-2/)

Key Takeaway: An expert polymorph screening service in the modern era is defined by its ability to predict before it tests, and to learn from every experiment. XtalPi's XtalGazerTM platform, through its deep AI models and automated closed loop, delivers this expert capability. It transforms polymorph screening from a risky, resource-intensive bottleneck into a strategic, data-driven accelerator that de-risks development, ensures regulatory confidence, and ultimately helps deliver better medicines with greater certainty and speed.
Conclusion: Defining the Future of Solid-State Expertise
The question of what defines an expert polymorph screening service has a new answer. It is no longer defined solely by laboratory footprint or years of empirical experience. Today, expertise is measured by predictive power, operational intelligence, and data-centricity.
XtalPi's scientific ecosystem for polymorph screening, centered on the XtalGazerTM platform, represents this new standard. By closing the loop between the virtual and the physical, between prediction and proof, this approach does not merely improve upon the old paradigm-it establishes a new one. It ensures that the solid form selected for development is not just the first one found, but the right one, backed by a comprehensive understanding of the entire polymorphic landscape. In the race to bring new therapies to market, this is not just an advantage; it is becoming a necessity.

For more information, please visit: https://www.xtalgazer.com/

XtalPi
The United States Greater Boston
100 Chestnut Street, Fl 3, Somerville, MA 02143
bd@xtalpi.com

Founded in 2015 by three MIT-trained physicists, XtalPi has established itself as a pioneering technological platform company at the intersection of quantum physics, artificial intelligence, and advanced robotics. Since its inception, XtalPi has prioritized sustained innovation in chemical discovery as the core of its mission, driven by increasing R&D investments and a commitment to building a world-class research platform.
Integrating quantum physics with AI, cloud computing, and automation, XtalPi has created a unified ecosystem to accelerate molecular breakthroughs across a wide range of industries. While accelerating pharmaceutical innovation remains a core strength of the platform, its versatility extends to new materials development, petrochemical process optimization, renewable energy innovation, agricultural science research, and even environmental challenges such as desertification management.
In June 2024, XtalPi achieved its landmark listing on the Hong Kong Stock Exchange (HKEX:2228), becoming the inaugural Chapter 18C-listed specialized technology company of HKEX. XtalPi maintains operational bases in Shenzhen, Shanghai, Beijing, Boston and Liverpool, with R&D personnel constituting over 70% of its workforce. The company deployed 200+ AI models, operates more than 10,000 square meters of wet laboratory facilities and has deployed proprietary AI-driven robotic workstation clusters at scale in Shenzhen and Shanghai.

This release was published on openPR.